Diagnostic Study of Lateral Ligament Complex Injury of Ankle
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Jun 28, 2020
Trial Information
Current as of May 21, 2025
Unknown status
Keywords
ClinConnect Summary
This clinical trial is looking at how well different testing methods can diagnose injuries to the lateral ligaments in the ankle, particularly for people who have ongoing problems with ankle stability due to past sprains. If you are over 16 years old and have a chronic injury (meaning it has lasted for a long time) from an ankle sprain, you may be eligible to participate in this study. However, if your injury is recent (less than 3 months), or if you have significant joint misalignment or advanced arthritis in your ankle, you would not qualify for this trial.
Participants in this study will undergo various diagnostic tests to help researchers understand which methods are the most accurate for identifying these types of injuries. The trial is currently recruiting, and individuals of all genders are welcome to join. By participating, you can contribute to important research that may help improve diagnosis and treatment for others with similar ankle issues in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Chronic lateral ankle ligament injury due to ankle sprain in patients over 16 years of age.
- Exclusion Criteria:
- • Acute and subacute injury of the lateral ligament complex of the ankle joint (less than 3 months), malalignment of ankle (more than 5 degrees), osteoarthritis (stage IV).
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Qinwei Guo
Principal Investigator
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials